Viewing Study NCT01116804


Ignite Creation Date: 2025-12-24 @ 9:08 PM
Ignite Modification Date: 2025-12-29 @ 1:16 PM
Study NCT ID: NCT01116804
Status: COMPLETED
Last Update Posted: 2022-12-15
First Post: 2010-05-03
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)
Sponsor: University Hospital, Ghent
Organization:

Study Overview

Official Title: Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)
Status: COMPLETED
Status Verified Date: 2022-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have several shortcomings. One important shortcoming is the time delay between successful treatment and radiological confirmation of this response. Often it takes several months for anatomical changes to occur and to be appreciated on morphological imaging such as CT or MRI (shrinkage of tumor, absence of contrast enhancement). Functional imaging by means of Fluor-18 deoxyglucose or Fluor-18 Choline (positron emitters, PET-scan) might be an early indicator of response. This "early" information might help to tailor treatment. For instance, if no response is induced, an early switch in therapy can be planned.

The present study investigates whether the routine PET-tracer (Fluor-18 deoxyglucose) and the experimental PET-tracer, Fluor-18 Choline help to predict response if a patient with inoperable primary liver cancer is treated (radionuclide therapy, biologicals).
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: